1 Department of Neurological Surgery, The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine , Miami, Florida.
J Neurotrauma. 2014 Mar 1;31(5):476-86. doi: 10.1089/neu.2013.3135. Epub 2013 Dec 19.
Traumatic brain injury (TBI) is characterized by histopathological damage and long-term sensorimotor and cognitive dysfunction. Recent studies have reported the discovery of the P7C3 class of aminopropyl carbazole agents with potent neuroprotective properties for both newborn neural precursor cells in the adult hippocampus and mature neurons in other regions of the central nervous system. This study tested, for the first time, whether the highly active P7C3-A20 compound would be neuroprotective, promote hippocampal neurogenesis, and improve functional outcomes after experimental TBI. Sprague-Dawley rats subjected to moderate fluid percussion brain injury were evaluated for quantitative immunohistochemical and behavioral changes after trauma. P7C3-A20 (10 mg/kg) or vehicle was initiated intraperitoneally 30 min postsurgery and twice per day every day thereafter for 7 days. Administration of P7C3-A20 significantly reduced overall contusion volume, preserved vulnerable anti-neuronal nuclei (NeuN)-positive pericontusional cortical neurons, and improved sensorimotor function 1 week after trauma. P7C3-A20 treatment also significantly increased both bromodeoxyuridine (BrdU)- and doublecortin (DCX)-positive cells within the subgranular zone of the ipsilateral dentate gyrus 1 week after TBI. Five weeks after TBI, animals treated with P7C3-A20 showed significantly increased BrdU/NeuN double-labeled neurons and improved cognitive function in the Morris water maze, compared to TBI-control animals. These results suggest that P7C3-A20 is neuroprotective and promotes endogenous reparative strategies after TBI. We propose that the chemical scaffold represented by P7C3-A20 provides a basis for optimizing and advancing new pharmacological agents for protecting patients against the early and chronic consequences of TBI.
创伤性脑损伤 (TBI) 的特征是组织病理学损伤以及长期的感觉运动和认知功能障碍。最近的研究报告发现了一类氨基丙基咔唑试剂 P7C3,它对成年海马中的新生神经前体细胞和中枢神经系统其他区域的成熟神经元都具有强大的神经保护作用。本研究首次测试了高活性 P7C3-A20 化合物是否具有神经保护作用,促进海马神经发生,并改善实验性 TBI 后的功能结果。对接受中度液压冲击脑损伤的 Sprague-Dawley 大鼠进行创伤后定量免疫组织化学和行为变化评估。P7C3-A20(10mg/kg)或载体在手术后 30 分钟内腹膜内给药,并在随后的 7 天内每天给药两次。P7C3-A20 的给药显著减少了总体挫伤体积,保留了易受伤害的神经元核(NeuN)阳性的损伤周围皮质神经元,并改善了创伤后 1 周的感觉运动功能。P7C3-A20 治疗还显著增加了 TBI 后 1 周同侧齿状回颗粒下区的 BrdU 和双皮质素 (DCX) 阳性细胞。TBI 后 5 周,与 TBI 对照组动物相比,用 P7C3-A20 治疗的动物表现出明显增加的 BrdU/NeuN 双标记神经元和改善的 Morris 水迷宫认知功能。这些结果表明 P7C3-A20 具有神经保护作用,并促进 TBI 后的内源性修复策略。我们提出,以 P7C3-A20 为代表的化学支架为优化和推进保护患者免受 TBI 的早期和慢性后果的新型药理学药物提供了基础。